Acumen Pharmaceuticals (ABOS) Assets Average (2021 - 2026)

Acumen Pharmaceuticals' Assets Average history runs 6 years deep, the most recent figure standing at $128.2 million for Q1 2026.

• In Q1 2026, Assets Average fell 42.17% year-over-year to $128.2 million; the TTM figure through Mar 2026 stood at $128.2 million (down 42.17% YoY), while the FY2025 annual figure was $180.9 million, down 34.11% from the prior year.
• Assets Average came in at $128.2 million for Q1 2026 at Acumen Pharmaceuticals, down from $132.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $305.5 million in Q1 2024 to a low of $128.2 million in Q1 2026.
• A 5-year average of $218.4 million and a median of $215.9 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 61.49% in 2024 and plunged 47.61% in 2025, its largest moves.
• Acumen Pharmaceuticals' Assets Average stood at $199.9 million in 2022, then soared by 49.18% to $298.2 million in 2023, then fell by 15.18% to $253.0 million in 2024, then sank by 47.61% to $132.5 million in 2025, then decreased by 3.24% to $128.2 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $128.2 million, $132.5 million, and $157.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison